Preclinical studies with Lu-177 picaga-Alb53-PSMA have shown promising tumor growth inhibition for over 3 weeks, indicating that optimized chelation strategies could enhance therapeutic outcomes [117]. The gene discussed is FOLH1; the disease is neoplasm.